Skip to content
About Us
Technology
Pipelines
Team
News
中文
2025年10月19日
Categories
News
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
2025-10-19
Multitude Ther…
Read More →
